Back to Results

EFTA00489768.pdf

Source: DOJ_DS9  •  Size: 101.3 KB  •  OCR Confidence: 85.0%
PDF Source (No Download)

Extracted Text (OCR)

From: Richard Kahn To: EM IES Subject: Re: Date: Thu, 17 Jan 2019 22:20:11 +0000 i asked JEE and he said to ignore so no need to follow up with jee.. thanks Richard Kahn ew or tel fax cell On Jan 17, 2019, at 4:04 PM, Thx Sent from my iPhone On Jan 17, 2019, at 3:50 PM, Richard Kahn < i will mention to jee when we speak next thanks Richard Kahn HBRK Associates Inc. 575 Lexington Avenue 4th Floor New York, NY 10022 tel fax cell On Jan 17, 2019, at 12:19 PM, > wrote: > wrote: > wrote: Christina requested I forward you the below `catch up' email. EFTA00489768 SioHebe cell: email: www.Mohebe.com @Bioliebe <1506365439123blobjpg> Fro To: Sent: Wednesday, January 16, 2019, 11:22:06 PM EST Subject: Catching Up Dear Jeffrey I hope you've been well. I wanted to update you on what I've been up to for the last two years. I was also hoping to talk with you to see if I might use the foundation's Lexington office conference room from time to time for my work and what I could provide in exchange for that. I am cc'ing Rich because I'm not sure if you still use this email? Since working for your foundation, I continued to publish as a joumalist writing mostly about genetic vectors (Newsweek, Tethonomy etc). I then set up an LLC that provides business development for labs that have reversed age-driven or degenerative diseases. Most of the therapies are genetic vectors, and have to show remarkable results at the mouse level and beyond. Regenerative medicine is a rapidly evolving field, and one that forces the medical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls. So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the US. And I am collaborating with a lab at the University of Pittsburgh that has reversed cirrhosis/ end stage liver disease in rats using the master transcription gene in hepatocytes. The concept of the latter gene vector is really intriguing in that a master transcription gene completely restored liver function by rebalancing genetic expression and thus proteostasis. While I don't really need an office at this point, I do need access to a conference room from time to time and it would be hugely helpful if I could access the foundation's. If there was some work that I could do for the foundation in exchange, I would be delighted to do that. It would be wonderful to catch up with you as well. all the best, EFTA00489769 cell: cmail Www.biohebe.com 0]BioHebe <1506365439123blobjpg> <I 506365439123blobjpr< I 506365439123blobjpg> EFTA00489770

Document Preview

PDF source document
This document was extracted from a PDF. No image preview is available. The OCR text is shown on the left.

Document Details

Filename EFTA00489768.pdf
File Size 101.3 KB
OCR Confidence 85.0%
Has Readable Text Yes
Text Length 2,761 characters
Indexed 2026-02-11T22:14:38.622487
Ask the Files